DoMore Diagnostic Welcomes Audun Ljone Henriksen as our new AI Engineer
OSLO – September 2, 2025 – DoMore Diagnostic is excited to announce that Audun Ljone Henriksen has joined our team as our new AI Engineer.
Audun holds a Master’s degree in Informatics, Machine Learning from the University of Bergen. His academic work has centered around deep learning, data science, and advanced system development. Prior to joining DoMore, Audun gained experience in both software engineering and machine learning, with a strong focus on applied AI research and development at the Institute for Cancer Genetics and Informatics (ICGI, Oslo University Hospital). His expertise spans programming, data analysis, and the implementation of cutting-edge machine learning models.
“We are very pleased to welcome Audun to the DoMore team,” said Torbjørn Furuseth, CEO and Co-founder of DoMore Diagnostic. “His excellent skills and hands-on experience with machine learning make him a perfect fit for our mission to transform precision medicine in cancer with AI-powered solutions.”
Audun also shared his enthusiasm about joining the company:
“I’m really looking forward to the journey ahead with DoMore Diagnostic. The team’s vision and dedication to personalize cancer treatment through AI is inspiring, and I’m excited to contribute to this important work.”
With Audun on board, DoMore Diagnostic strengthens its ability to deliver innovative AI solutions that enhance precision and efficiency in cancer prediction.
About DoMore Diagnostics
DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Our unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor.
About Colorectal Cancer and Histotype Px® Colorectal
Colorectal cancer is the third most common and second most deadly cancer but has seen little innovation in diagnostics and treatment in the last decades. Adjuvant chemotherapy (ACT) may be provided after primary surgery to prevent the disease from recurring, however overtreatment is prevalent with up to 85% of patients with stage II and stage III not benefiting from ACT and only suffering side effects.
Histotype Px® is an advanced deep learning algorithm that analyzes digital histology slides, separating patients into distinct Low, Intermediate and High-risk groups to guide ACT treatment decisions. Data previously published in The Lancet and The Lancet Oncology showed that the test can accurately predict survival outcomes in colorectal cancer patients. Histotype Px® Colorectal was developed to provide clinicians with valuable information to guide personalized treatment decisions and improve patient outcomes.
Histotype Px is a registered trademark in the European Union. Trademark registration status may vary by country.
For more information, please visit:
www.domorediagnostics.com
LinkedIn
The Lancet publication
The Lancet Oncology publication
Contact:
Torbjørn Furuseth, MD
torbjorn.furuseth@domorediagnostics.com